The use of the MPTP-treated mouse as an animal model of parkinsonism

34Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

The MPTP-treated mouse has proven to be a valuable model of parkinsonism. For example, C57 black mice treated with MPTP exhibit a large decrement in the neostriatal content of dopamine and its metabolites, a marked reduction in the capacity of neostriatal synaptosomal preparations to accumulate [(3H]dopamine, a large decrease in neostriatal tyrosine hydroxylase activity, a marked loss of nerve cells in the zona compacta of the substantia nigra, and pronounced behavioral deficits. These biochemical, pathological and behavioral deficits are similarly observed in MPTP-treated primates and in humans with idiopathic parkinsonism. A great deal of our current knowledge concerning MPTP has come from experimentation carried out in the mouse.

Cite

CITATION STYLE

APA

Heikkila, R. E., & Sonsalla, P. K. (1987). The use of the MPTP-treated mouse as an animal model of parkinsonism. Canadian Journal of Neurological Sciences, 14(3 SUPPL.), 436–440. https://doi.org/10.1017/s0317167100037860

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free